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Hypersensitivity drug reactions (HDRs) are the adverse effect of pharmaceuticals that
clinically resemble allergy. HDRs account for approximately 1/6 of drug-induced adverse
effects, and include immune-mediated (“allergic”) and non-immune-mediated (“pseudo
allergic”) reactions. In recent years, the severe and unpredicted drug adverse events
clearly indicate that the immune system can be a critical target of drugs. Enhanced
prediction in preclinical safety evaluation is, therefore, crucial. Nowadays, there are
no validated in vitro or in vivo methods to screen the sensitizing potential of drugs
in the pre-clinical phase. The problem of non-predictability of immunologically-based
hypersensitivity reactions is related to the lack of appropriate experimental models rather
than to the lack of -understanding of the adverse phenomenon. We recently established
experimental conditions and markers to correctly identify drug associated with in vivo
hypersensitivity reactions using THP-1 cells and IL-8 production, CD86 and CD54
expression. The proposed in vitro method benefits from a rationalistic approach with
the idea that allergenic drugs share with chemical allergens common mechanisms of
cell activation. This assay can be easily incorporated into drug development for hazard
identification of drugs, which may have the potential to cause in vivo hypersensitivity
reactions. The purpose of this review is to assess the state of the art of in vitro models
to assess the allergenic potential of drugs based on the activation of dendritic cells.
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INTRODUCTION
Adverse drug reactions (ADRs) are defined by the World Health Organization as “any
noxious, unintended, and undesired effect of a drug that occurs at doses used for prevention,
diagnosis, or treatment”. ADRs can be categorized into type A—predictable (about 80% of
all ADRs), and type B—unpredictable, reactions. Type A (predictable) reactions are usually
dose-dependent, related to the known pharmacologic actions of the drug, and occur in
otherwise health subject while type B (unpredictable) reactions are generally dose independent,
are unrelated to the pharmacologic actions of the drugs, and occur only in susceptible
subjects. Unpredictable reactions are subdivided into drug intolerance, drug idiosyncrasy, drug
allergy and pseudo-allergic reactions (Khan and Solensky, 2010). It is difficult to distinguish
between pseudo allergic reactions and true immunologically mediated allergic reactions, but
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the first one lack immunological specificity (Warrington
and Silviu-Dan, 2011). The Gell and Coomb’s classified
hypersensitivity reactions into 4 types and this classification
system includes:
• Type I reactions: immediate-type reactions mediate by
immunoglobulin E (IgE) antibodies. Drug IgE complex bind
to mast cells with release of histamine and inflammatory
mediators, resulting in anaphylaxis, urticarial, angioedema,
bronchospasm. Examples of drugs include penicillin and
cephalosporins.
• Type II reactions: cytotoxic reactions mediated by drug-
specific immunoglobulin G (IgG) or immunoglobulin M
(IgM) antibodies. Specific IgG or IgM antibodies are directed
at drug-hapten coated cells, resulting in anemia, cytopenia,
thrombocytopenia. Examples of drugs includes hydralazine,
methyldopa and procainamide.
• Type III: immune-complex reactions. Tissue deposition of
drug-antibody complexes result in complement activation
and inflammation (i.e., serum sickness, vasculitis, fever, rash,
arthralgia, lupus). Examples of drugs include penicillin,
sulphonamides, hydralazine and procainamide.
• Type IV reactions: delayed-type hypersensitivity reactions
mediated by cellular immune mechanisms. MHC presentation
of drugs to T cells results in the release of cytokine and
inflammatory mediators, which recruit inflammatory cells
(i.e., contact sensitivity, skin rashes, organ-tissue damage).
Type IV reactions can be divided in subcategories, with the
activation and recruitment of monocytes, eosinophils, CD4+
or CD8+ T cells, and neutrophils (Pichler, 2003a; Riedl and
Casillas, 2003; Warrington and Silviu-Dan, 2011). Examples
of drugs include neomycin, penicillin and benzocaine.
In vivo tests like patch, prick and intra-cutaneous tests often
do not yield positive reactions for the diagnosis of drug allergy
and lacks optimal sensitivity that still remains a major problem
in daily clinical practice (Sachs et al., 2002). For these reasons,
in vitro stimulation could be required as a complementary
diagnostic test, as emerged from some studies (Torres et al., 2003;
Romano et al., 2004; Sachs et al., 2004).
Nowadays there are no validated in vivo or in vitro methods
for assessing the sensitizing potential of a drug during the pre-
clinical phase, although the important adverse reactions directly
linked to immune-mediated hypersensitivity and autoimmunity
reactions. Available in vitro tests mainly refer to the effector phase
of immediate-type drug allergic reactions, such as the CAST-
ELISA R© (Kubota et al., 1997), which is based on the presence of
specific IgE antibodies and the BASO-Test R© (Pâris-Köhler et al.,
2000), based on the activation of basophils like.
Currently, the popliteal lymph node assay (PLNA), or
its modifications, can be used in research studies for the
identification of drugs, which may be potential allergens, or
may cause autoimmunogenic reactions (Warbrick et al., 2001).
However, no reliable models or general strategy and assays
(including the PLNA) are at present available (or validated)
and requested by regulatory agencies. PLNA appears to be very
useful for the assessment of the potential of drug to initiate an
immune response. The simplest, the primary PLNA, measures
popliteal lymph node hyperplasia after subcutaneous injection
of a chemical into the footpad of a mouse or rat. The PLN-
index is obtained with the ratio of weight or cell number of
the draining lymph node of the chemical-treated animals over
the vehicle-treated animals (Pieters, 2001). With the primary
PLNA, the involvement of specific T cells cannot be assessed;
therefore, in a previously sensitized animal, a secondary PLNA
must be performed by measuring the PLN index of a chemical.
In this assay, purified and irradiated T cells from sensitized
syngeneic donors are injected subcutaneously into the footpad
of naïve acceptor mice 1 day before injection of the chemical
or its active metabolite. Finally, the modified PLNA, defined
reporter antigens TNP-OVA (T cell-dependent antigen) and
TNP-Ficoll (T cell-independent antigen) are used to distinguish
between sensitizing and non-sensitizing (IgG1-response or not
to TNP-Ficoll, respectively) drugs (Albers et al., 1997). The
primary PLNA is particularly suitable as preclinical screening
assay, but it cannot distinguish between strong irritants and
sensitizing compounds. Also the more complicated modified
PLNA may be used as screening assay, and it has additional
advantages over the primary PLNA including (a) the parameters
measured (antibody production) are immunologically more
relevant than lymph node weight or cell number; (b) the immune
response can be measured without knowing the nature of
the neo-antigens and it can discriminate between sensitizing,
non-sensitizing and complete innocent chemicals. In any case,
some of the compounds known to cause immune adverse
effects in humans, however, failed to induce a positive PLNA
response, leading to refinements of the technique to include
pretreatment with enzyme inducers, depletion of CD4+ T
cells or additional endpoints such as histological examination,
lymphocyte subset analysis and cytokine fingerprinting (Ravel
and Descotes, 2005).
It is well known that immunological adverse drug reactions
are rare (Gruchalla, 2001; Pichler, 2003b) but anyway they are
generally able to cause a lot of discomfort to patients and may
indeed be really dangerous. The withdrawal from the market of
drug is also an important economic issue due to the extremely
high costs associated with the development of a drug (Pieters,
2007). The development of alternative in vitro assays to detect the
sensitization potential during the development phase of a drug
would increase safety and possibly reduces the risk of market
withdrawal (Corti et al., 2015).
Traditional drugs have low molecular weights (<1000 Da)
and as a such they are too small to be “seen” by T cells.
Therefore, low molecular weight compounds have first to
bind to a protein before they will become visible to T cells
(Weltzien et al., 1996; Pichler, 2002). In addition, drugs may
alter protein structure, the process of antigen presentation,
or may, by causing cellular or organ damage, release auto-
antigens (e.g., DNA or histones) for which no tolerance exists
(Pieters, 2007), favoring the development of hypersensitivity
reactions.
This review will focus on the state of the art of available in vitro
models to assess the potential of drugs to induce hypersensitivity
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for diagnostic purposes and on the potential in vitro test for the
pre-clinical assessment.
STATE OF THE ART OF IN VITRO MODELS
TO ASSESS DRUG-INDUCING
HYPERSENSITIVITY
The cells involved and mediators released during the different
phases of hypersensitivity reactions can be assessed using in
vitro diagnostic tests. The methods used for the diagnosis of
HDR depend on the mechanism involved and the kinetic of the
reaction. As shown in Figure 1, in vitro diagnostic tests can be
divided in test able to identify the drugs but only at the resolution
of the hypersensitivity reaction, and in in vitro assays, which
allow to determining the HDR risks before drug administration.
Is important tomention that in vitro tests for the identification
of non-immediate reactions (NIR) are not commercially available
and therefore standardization is not possible (Mayorga et al.,
2016).
IN VITRO DIAGNOSTIC TESTS
HLA-Allele Determination
The human leukocyte antigen (HLA) system is a gene complex
encoding the major histocompatibility complex (MHC) proteins
in humans. HLA genes are highly polymorphic, which means
that they have many different alleles, allowing them to fine-
tune the adaptive immune system. HLA genotyping is based
on reverse sequence-specific oligonucleotide-polymerase chain
reaction using DNA from peripheral blood.
Pharmacogenetic testing is not widely used in routine
clinical practice to optimize drug choice or clinical management
(Philipps, 2006). This gap between scientific knowledge and
clinical application may be explained by the fact that the
successful incorporation of a pharmacogenetic test into routine
practice requires a combination of high-level evidence that can be
generalized to diverse clinical setting, wide-spread availability of
cost-effective and reliable laboratory tests, and effective strategies
incorporate testing into routine clinical practice (Mallal et al.,
2008).
Several clinical studies, as reported in the review by Mayorga
et al. (2016), correlate hypersensitivity reaction caused by
pharmaceuticals with the presence of different HLA allele. In
particular HLA-B∗57:01 has been found to be associated with
abacavir hypersensitivity; for carbamazepine, the most important
association has been established with HLA-B∗15:02 and HLA-
A31:01, while HLA-B∗58:01 allele has been associated with
allopurinol hypersensitivity.
Prospective HLA-allele screening may be widely useful, but
there are some controversial points like the cost-effectiveness
of the test, that depend on several estimates that vary among
populations, the health care setting, and also the availability of
appropriate laboratory assays (Martin et al., 2006; Hammond
et al., 2007).
Lymphocyte Transformation Test (LTT)
The LTT measures the in vitro proliferative response of T cells
that emerge from the clonal expansion of naïve T cell, after drug
FIGURE 1 | Classification of in vitro models able to assess drug-inducing hypersensitivity reactions. In vitro diagnostic tests can be divided in test able to
identify the culprit drugs at the resolution of the reaction, and methods that allow to determining the individual risk of HDR before drug administration. On the other
hand, some in vitro methods may be used in the pre-clinical phase of drug development for hazard identification of potential to induce hypersensitivity reactions.
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exposure (Nyfeler and Pichler, 1997; Lanzavecchia and Sallusto,
2000). The proliferative response of lymphocytes is measured
by the incorporation of 3H-thymidine during DNA synthesis
or by carboxyfluorescein diacetate succimidyl ester (CFSE). The
most widely studied drugs are betalactams (Mayorga et al., 2016).
The LTT limits are represented by the use of radioactivity,
which limits the application of the method to specific research
laboratories, it is a quite long procedure, the sensitivity is quite
low (60–70%), and it depends upon the conditions employed
(Nyfeler and Pichler, 1997; Romano et al., 1997; Beeler and
Pichler, 2007).
Enzyme-Linked Immunosorbent Spot
(ELISpot) Assay
ELISpot is a technique used to determine the number of
cells able to produce cytokines and cytotoxic markers after
their activation by the drug or its metabolites (Sullivan et al.,
2015). Clinical studies report the use of IFN-γ ELISpot to
diagnose non-immediate reactions to betalactames; granzyme
B and granulysin ELISpot for evaluating severe cutaneous
reactions induced by amoxicillin, ciprofloxacin, carbamazepine,
sulphonamides, allopurinol, mefenamic acid, oxipurinol, and
lamotrigine (Zawodniak et al., 2010; Porebski et al., 2013).
One advantage of this in vitro test is that drug-reactive T cells
remain detectable for long time after the reaction and could be
appropriate for high throughput screening but to improve the
accuracy of the test, two or more cytokines determination could
be necessary.
Cell Markers and Cytokine Release
After drug stimulation, T-cells express or up-regulate a number
of surface molecules and produce different inflammatory
mediators. Cytokine expression and secretion can be evaluated by
several methods such as reverse transcription polymerase chain
reaction (RT-PCR), flow cytometric analysis, and enzyme linked
immunosorbent assay (ELISA). RT-PCR is used to measure
cytokine at the transcriptional levels, while flow cytometric
analysis are used to study intracellular cytokines and cell surface
markers. Finally, ELISA is used to measure the amount of
secreted cytokines in cell culture supernatants (Khalil et al.,
2008).
Sachs et al. demonstrated that accumulation of eosinophils
following IL-5 secretion, and to a lesser extent also with IL-10 and
IFN-γ, from drug-specific stimulated T cells is a characteristic
histological feature of drug-induced skin eruption. In vitro
determination of drug-specific IL-5 secretion by peripheral blood
mononuclear cells may be relevant for the detection of in
drug-induced maculopapular exanthems (Sachs et al., 2002).
CD69 is up-regulated after 48–72 h, and its determination
by flow cytometry correlates with LTT for betalactames,
sulphamethoxazole and carbamazepine HDR (Beeler et al.,
2008). CD69 may be used for the evaluation of non-immediate
reactions.
These in vitro tests represent important tools for diagnosis.
They are, however, used mainly as research methods rather than
as routine procedures. It must be also taken into consideration
the timing of sample collection, which is critical as mediators can
be secreted in transitory peaks with variants in the maintenance
of detectable levels (Mayorga et al., 2006), and chemokines and
cytokines can be degraded by protease (Niwa et al., 2000).
Other In vitro Tests
Other in vitro tests have been proposed for the study of drug
allergy reactions. Among these the cellular allergen stimulation
test (CAST-ELISA R©) for the measurement of leukotrienes
after peripheral blood leukocyte stimulation, basophil histamine
release tests and a basophil activation test (BASO-Test R©) can
be mentioned. CAST-ELISA R© is commercially available but
it has not been sufficiently evaluated to recommend as a
standard investigation outside the context of prospective studies.
Basophil activation markers using fluorescence activated cell
sorter analysis are currently being evaluated for certain type
of drug allergic reactions but there seems to be no evidence
currently of any advantage of these tests over skin testing
(Mirakian et al., 2009).
POTENTIAL IN VITRO PRE-CLINICAL
TESTS TO ASSESS HYPERSENSITIVITY
None of the in vitro methods mentioned above are, however,
useful in preclinical safety assessment. It will important to
have in vitro methods to screen drugs for their potential to
induce hypersensitivity reactions. In the last decade an incredible
progress has been made in the development of non-animal tests
to assess contact hypersensitivity, and some tests have been
formally validated. Methods based on the use of dendritic cells
and the T cell priming are discussed below.
The T Cell Priming Assay
Chemicals can elicit T-cell-mediated diseases, including adverse
drug reactions. The T cell priming assay (TCPA) was developed
primarily for the identification of contact allergens within
the integrated EU project SENS-IT-IV. This assay allows the
detection of chemical-specific T cells in naive human peripheral
T-cell population by measurement of proliferation and, at the
single cell level, of IFN-γ production in CD4+ and CD8+ T
cells. This assay may be a valuable, highly specific element in an
integrated testing strategy for the predictive in vitro identification
of contact allergens and possibly drugs that cause T cell-mediated
adverse drug reactions (Dietz et al., 2010; Martin et al., 2010;
Richter et al., 2013).
Myeloid U937 Skin Sensitization Test
(MUSST) and Modified MUSST (mMUSST)
The MUSST is an in vitro method proposed to assess skin
sensitization. Dendritic cell activation following exposure to
sensitizers was modeled in the U937 human myeloid cell
line by measuring the induction of the expression of CD86
by flow cytometry after 48 h of chemical treatment. A test
substance is predicted to have a dendritic cell activating
potential indicative of being a sensitizer when CD86 induction
exceeds the threshold of 1.5-fold with respect to vehicle treated
cells at any tested concentration showing a cell viability ≥70
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FIGURE 2 | The THP-1 activation assay tier approach. Following 24 h of THP-1 chemical/drug treatment, the effect on IL-8 release and CD86 expression are
investigated. If positive (statistically significant release of IL-8 at any concentration and/or a SI ≥ 1.5 for CD86), the chemical/drug will be considered as sensitizer. If
negative, in order to exclude any activation, IL-8 release and CD86 expression at 48 h (statistically significant release of IL-8 at any concentration and/or a SI ≥ 1.5 for
CD86) or CD54 expression at 24 h (SI ≥ 2.0) or alternatively IL-8 mRNA expression (2−11CT > 3.0) at 3 h should be assessed. Only if negative results were obtained
in all parameters, the chemical/drug will be considered as non-sensitizer.
TABLE 1 | Time of IL-8 release and CD86 expression of the selected drugs
in THP-1 assay.
Chemical CV75 (µg/ml) Statistical significant
IL-8 release
CD86
expression
Streptozotocin >2000 24 h 24 h
Sulfamethoxazole >1000 48 h 48 h
Procainamide >2000 24 h 24 h
Ofloxacin >1000 24 h 24 h
Neomycin >2000 24 h –
Clonidine 750 24 h 24h
Methyl salicylate >1000 24 h 24h
Probenecid 600 24 h 48h
Metformin >2000 – –
106/ml cells were treated for 24–48 hwith increasing concentrations of the selected drugs.
Cell viability was assessed by PI staining. CV75 (the concentration resulting in 75% of cells
viability compared to vehicle treated cells) was calculated by linear regression analysis
of data. IL-8 release was measured by ELISA. CD86 expression was evaluated by flow
cytometric analysis. Original data are present in Corti et al. (2015).
Legend: – no induction observed.
% in at least two independent experiments (Urbisch et al.,
2015).
In the modified version of the MUSST (mMUSST), a
test substance is predicted to have a dendritic cell activating
potential when CD86 induction exceeds a threshold of 1.2-
fold (Bauch et al., 2012). Among more than 145 substances
available from these two in vitro assays, also some drug
sensitizers, namely benzocaine, hydroquinone, p-benzoquinone
and diphenylclopropenone were tested and resulted correctly
classified with the MUSST (Bauch et al., 2012; Natsch et al., 2013;
Urbisch et al., 2015).
The Human Cell Line Activation Test
(h-CLAT)
The h-CLAT quantifies changes in CD86 and CD54 expression
in the human THP-1 cell line following 24 h exposure to the
test chemical. The changes in surface marker expression are
measured by flow cytometry. Cytotoxicity measurement is
conducted concurrently to assess whether up-regulation of
surface maker expression occurs at sub-cytotoxic concentrations.
The prediction model use the relative fluorescence intensity of
surface markers compared to solvent control to discriminate
between sensitizers and non-sensitizers. Among the 166
substances tested in this in vitro assay, the allergenic drugs
benzocaine, clofibrate, pyridine, hydroquinone, p-benzoquinone
and diphenylclopropenone resulted correctly classified
(Nukada et al., 2012; Takenouchi et al., 2013; Urbisch et al.,
2015).
Overall, even if the number of drugs tested is very limited,
data suggests that pharmaceuticals may share with chemical
allergens a common mechanism of action that activates dendritic
cells, and support the possibility to use these in vitro methods
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FIGURE 3 | Role of ROS in chemical allergen-induced DC activation.
also for the identification of drugs potentially associated with
hypersensitivity reactions.
The THP-1 Activation Assay
As mentioned above, most drugs are small molecules and are
by themselves, not immunogenic. During the haptenization
process, these small molecules bind to carrier proteins to form
a complete immunogenic complex (Chang and Gershwin, 2010).
The hypersensitivity reaction then requires the activation and
maturation of dendritic cells (DCs), which will then drive the
activation of specific T cells (Martin, 2012). DCs are antigen-
presenting cells (APC) that play a central role in the initiation and
regulation of adaptive immune responses. Following the contact
with antigens, DCs undergo a process of maturation associated
with the expression of several co-stimulatory molecules on the
membrane such as CD80, CD86 and CD40, various adhesion
molecules (CD2, CD11a, CD54, CD58), and secrete different
cytokines, including IL-1β and IL-8 (Quah and O’Neill, 2005).
Once activated, DCs migrate into the regional lymph node or in
the spleen, where they present antigen to specific T lymphocytes,
through MHC class II molecules (Ryan et al., 2007) and co-
stimulatory adhesion molecules expressed on both DC (i.e.,
CD86) and T cell (i.e., CD28) to ensure the necessary contact to
achieve full T-cell activation. Following stimulation, a clone of T
cells is produce with the ability to react to the antigen, resulting
in the clinical manifestation of HDR.
Within the European project SENS-IT-IV, we have previously
established an in vitro method able to identify contact and
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respiratory allergens based on the use of the human THP-1
cell line (the same cell line used in the h-CLAT) and IL-8
release: the THP-1 activation assay (Mitjans et al., 2008, 2010).
IL-8 is a potent chemotactic peptide for neutrophils as well as
for T lymphocytes, basophils, and NK cells. In parallel to IL-8
production, several of the proposed in vitro methods, including
the ones mentioned above, are based on DC and CD86 alone
or in combination with CD54 expression for the identification
of chemical sensitizers, due to their roles in antigen presentation
and T cell activation.
Based on the notion that drug sensitizers and chemical
sensitizers share the same mode of action, we recently
investigated the possibility to use the THP-1 activation assay
developed for skin and respiratory sensitizers, for the in vitro
identification of pharmaceuticals, which may be associated with
in vivo drug hypersensitivity reactions (Corti et al., 2015).
It is well known that allergen drugs share with chemical
allergens common mechanisms of cell activation and for reason
we propose the THP-1 activation assay also for the hazard
identification of immune-mediated hypersensitivity reactions
induced by pharmaceuticals. Drugs were selected on the basis
of clear in vivo immune-adverse reactions reported in literature,
post-marketing data or labeling information, and on the
commercial availability as pure drugs. Clonidine, ofloxacine,
procainamide, streptozotocin, sulfamethoxazole which have been
associated with a relatively high incidence of immune-mediated
hypersensitivity reactions (Weaver et al., 2005), methyl salicylate
and probenecid, which have been reported to cause irritant
or allergic contact dermatitis and anaphylactic reactions (Corti
et al., 2015), have been tested. We developed a strategy based
on IL-8 production, CD86 and/or CD54 expression in THP-
1 cells useful for the in vitro identification of drug sensitizers
(see Figure 2). There are some important differences with the
previous mentioned h-CLAT. First, the method we use to
calculate CD86 and CD54 expression is different from h-CLAT
protocol: in h-CLAT only the MFI is considered, while we also
include the percentage of positive cells. The second point is the
concentration tested. In fact, we observed that quite often a CV75
couldn’t be reached with drugs compared to chemicals, meaning
that drugs are less cytotoxic. The test we developed allowed the
correct identification of all the selected drugs tested, including
sulfamethoxazole, probenecid and procainamide for which
metabolism is needed. Penicillin G, another drug frequently
associated with hypersensitivity reactions (Siegel and Coleman,
1957), was previously tested, and found to be able to induced a
dose-related release of IL-8 following 48 h of exposure (Mitjans
et al., 2008).
Exposure of THP-1 cells to sensitizing drugs results in most
cases in dose related release of IL-8 and increase in CD86
expression, with some differences among drugs, markers and
times of exposure. As shown in Table 1, the combination of
both IL-8 and CD86 expression allows the identification of all
drugs tested. The use of IL-8 mRNA expression at 3 h or CD54
expression at 24 h may offer an alternative to the 48 h exposure
and increase our confidence in the negativity of a drug (see
Corti et al., 2015). The expression of IL-8 mRNA at 3 h is based
on previous observation we made on chemical allergens failing
to induce the release of IL-8: all chemicals sensitizers tested
including pro-hapten induced IL-8 mRNA at 3 h (Galbiati et al.,
2012).
Using streptozotocin as reference drug to study the
mechanisms of action, we could demonstrate a key role for
p38 mitogen-activated protein kinase (p38 MAPK) and PKC-β
activation in streptozotocin-induced IL-8 release and CD86
expression (Corti et al., 2015), confirming previous results
obtained with chemical allergens (Mitjans et al., 2008; Corsini
et al., 2014).
Evidence indicates that oxidative stress is involved in
chemical-induced skin allergic and inflammatory diseases
(Okayama, 2005; Byamba et al., 2010). Chemical-induced
oxidation of the cell surface thiols appears to be one of the triggers
of DC maturation, resulting in intracellular redox imbalance
that generate stress-related signal (Figure 3). The Keap1/Nrf2-
signaling pathway is dedicated to the detection of electrophilic
stress in cells leading to the up-regulation of genes involved in
protection or neutralization of chemicals reactive species (Natsch
and Emter, 2007). It has been shown in human monocyte-
derived dendritic cells that chemical sensitizers induced oxidative
stress measured by the glutathione GSH/GSSG ratio, as a redox
marker (Mizuashi et al., 2005). The reduction of the glutathione
GSH/GSSG ratio was accompanied by CD86 up-regulation
and p38 MAPK activation, suggesting that the electrophilic
properties of chemicals sensitizers may be perceived by DCs as
a danger signal leading to DC maturation (Sasaki and Aiba,
2007). Engagement of certain Toll like receptors (TLR1, 2, and
4) leads to mitochondrial translocation of the signal adaptor
TRAF6. At the mitochondria, TRAF6 interacts with ECSIT, a
protein implicated in the assembly of complex I, leading to
its ubiquitylation, which results in increased ROS production.
TABLE 2 | Drugs known to induce hypersensitivity and resulted positive in
DC-based in vitro methods.
Drug h-CLAT MUSST mMUSST THP-1 activation
assay
Benzocaine * #
Clofibrate x
Pyridine *
Hydroquinone * #
p-Benzoquinone * # +
Diphenylclopropenone * #
Streptozotocin §
Sulfamethoxazole §
Procainamide §
Ofloxacin §
Neomycin §
Clonidine §
Methyl salicylate §
Probenecid §
Metformin §
*, Nukada et al. (2012); x, Takenouchi et al. (2013); #, Natsch et al. (2013); +, Bauch et al.
(2012); §, Corti et al. (2015).
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Proteins that are reversibly modulated by ROS are of high
interest. In this context, protein kinases and phosphatases, which
act co-ordinately in the regulation of signal transduction through
the phosphorylation and dephosphorylation of target proteins,
have been described to be key elements in ROS-mediated
signaling events. In particular, PKC isoforms have been shown to
contain a unique structural feature that is susceptible to oxidative
modification (Cosentino-Gomes et al., 2012). The high levels
of cysteine residues render the regulatory domain susceptible
to redox regulation (Gopalakrishna and Jaken, 2000; Giorgi
et al., 2010). Currently, evidence supports the direct activation
of different PKC isoforms by ROS generation; in particular the β
isoform is able to induce ROS generation through mitochondrial
damage (Pinton et al., 2007).
To summarize the drugs tested in the preclinical available in
vitro methods and known to be able to induce hypersensitivity
reactions, a list is reported in Table 2.
CONCLUSION
Develop a new pharmaceutical entity has many possibilities
of failure and is a very expensive process. Methods and/or
models to assess the hazard of hypersensitivity reactions by
pharmaceuticals are not yet validated (or requested on a routine
basis). The assessment of hypersensitivity of pharmaceuticals
would benefit from a rationalistic approach using clear and
linear test methods that are based on immunological knowledge
and read out parameters. There are many in vitro tests that
can help in diagnosis and identification of the pharmaceuticals
able to cause a hypersensitivity reaction, and among of these,
we established, using the THP-1 cell line as surrogate of
dendritic cells, experimental conditions and markers to correctly
identify drug sensitizers. The THP-1 cells assay can be easily
incorporated into drug development to identify drugs that
may have the potential to cause systemic hypersensitivity
reactions.
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